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Background: Rheumatoid arthritis (RA) is a chronic, progressive joint disease, which frequently leads to irreversible
joint deformity and severe functional impairment. Although patients are treated according to existing guidelines
and reach clinical remission, erosive progression still occurs. This demonstrates that additional methods for
prognostication and monitoring of the disease activity are needed. Bone marrow edema (BME) detected by
magnetic resonance imaging (MRI) has proved to be an independent predictor of subsequent radiographic
progression. Guiding the treatment based on the presence/absence of BME may therefore be clinically beneficial.
We present the design of a randomized controlled trial (RCT) aiming to evaluate whether an MRI-guided treatment
strategy compared to a conventional treatment strategy in anti-CCP-positive erosive RA is better to prevent progression
of erosive joint damage and increase the remission rate in patients with low disease activity or clinical remission.
Methods/design: The study is a non-blinded, multicenter, 2-year RCT with a parallel group design. Two hundred
anti-CCP-positive, erosive RA patients characterized by low disease activity or remission, no clinically swollen
joints and treatment with synthetic disease-modifying antirheumatic drugs (DMARDs) will be included. Patients
will be randomized to either a treatment strategy based on conventional laboratory and clinical examinations
(control group) or a treatment strategy based on conventional laboratory and clinical examinations as well as MRI
(intervention group). Treatment is intensified according to a predefined treatment algorithm in case of inflammation
defined as a disease activity score (DAS28) >3.2 and at least one clinically swollen joint (control and intervention
groups) and/or MRI-detected BME (intervention group only). The primary outcome measures are DAS28 remission
(DAS28 < 2.6) and radiographic progression (Sharp/vdHeijde score).
Discussion: The perspectives, strengths and weaknesses of this study are discussed.
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Rheumatoid arthritis (RA) is a chronic inflammatory
joint disease, which primarily affects the small joints
of the hands and feet, with a prevalence of 0.5-1.0% in
the adult population [1]. Patients typically experience
joint pain, disability and loss of quality of life, and they
are at risk of developing progressive joint damage,
which eventually leads to irreversible joint deformity
and severe functional impairment [2]. The long-term
prognosis of RA is poor. After 20 years of disease, 80%
of the patients will have evidence of disability, and
19% are severely disabled [3]. Approximately 50% of
the patients will have stopped working 10 years after
disease onset [4].
Erosive joint damage occurs early in the disease
course and precedes subsequent progressive joint damage
and functional limitation [5,6]. Other known prognostic
factors of radiographic damage are existing radiographic
damage, shared epitope alleles, rheumatoid factor (RF)
and/or anti-citrullinated peptide (anti-CCP) antibody
positivity and biochemical signs of inflammation [in-
creased erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP)] at disease onset [7]. However,
even though these prognostic factors are all associated
with poor radiographic outcome on a group level, at
the individual patient level they cannot distinguish
which patients will progress or not. MRI bone marrow
edema, which reflects inflammatory infiltrates in the
bone marrow (osteitis) [8,9], has proved to be a strong
independent predictor of radiographic progression in
patients with early RA [10-12] and may therefore have
significant prognostic value at an individual level.
The modern treatment strategy involves early and ag-
gressive treatment with frequent clinical follow-up aim-
ing at reaching a target of clinical remission in patients
with early RA and at least a state of low disease activity
in patients with longstanding RA [13]. This treat-to-
target strategy has been shown to slow the destructive
progression and prevent functional loss [14,15]. How-
ever, it has been demonstrated that 20-30% of patients
who reach the treatment target of clinical remission
still show progressive erosive joint damage, no matter
what remission criteria are used [16,17].
Thus, the clinical and laboratory methods currently
used in routine clinical practice for assessments of dis-
ease activity are not sufficiently sensitive. This illus-
trates and emphasizes that new more sensitive methodsfor monitoring and prognostication are highly needed
to ensure that the treatment can be optimally adjusted
in order to achieve the best possible outcome.
MRI depicts the pathological changes in all tissues in-
volved in RA and shows greater sensitivity in detecting
inflammatory and destructive changes than both clinical
examination and x-ray [18,19]. This superior sensitivity
of MRI compared to conventional clinical examinations
and radiographs, combined with the knowledge that
MRI detected BME is a strong predictor of subsequent
radiographic progression, has generated the hypothesis
that adding MRI to the conventional clinical and labora-
tory examinations and intensifying treatment in the
presence of subclinical MRI BME will reduce radio-
graphic erosive progression and improve the patient’s
functional level.
The aim of the present study is in an RCT to evaluate
whether an imaging-based treat-to-target treatment
strategy using MRI and DAS 28 (Disease Activity Score
involving 28 joints) can prevent progression of erosive
joint damage and increase the remission rate in patients
with RA compared to a treat-to-target treatment strategy
guided only by DAS 28. To our knowledge, this is the
first study using MRI as a guide for treatment intensifi-
cation in RA patients.
Methods/design
The study is conducted in Denmark as a multicenter,
non-blinded, 2-year, RCT with a parallel group design. A
diagram of the phases (enrollment, allocation, follow-up,
analysis) through the trial is shown in Figure 1.
Participants
Participants will be recruited to the study from the
rheumatology outpatient clinics at ten Danish Hospitals:
Copenhagen University hospitals at Glostrup, Slagelse,
Gentofte, Bispebjerg-Frederiksberg and Køge; Aarhus
University hospitals at Aarhus and Silkeborg; university
hospitals of Southern Denmark at Odense and Graasten;
Ålborg University hospital at Hjørring. The rheumatolo-
gist will ask eligible patients at a routine visit whether
they would consider participating in the study. Oral and
written information will be provided. If the patient
agrees to participate, declaration of informed consent is
signed. Patients will not be recruited through advertising.
A screening visit is carried out to ensure that patients
meet the criteria for participation.
Figure 1 Flow chart. Flow chart through the phases of the IMAGINE-RA study from enrollment to analysis.
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to the ACR (American College of Rheumatology)/EULAR
(European League Against Rheumatism) 2010 criteria
[20], ≥18 years of age, low disease activity/remission (de-
fined as DAS28-CRP <3.2 and no clinically swollen joints
assessed clinically by the treating rheumatologist), bone
erosion on radiography (described by the local radiologist),
anti-CCP positivity (above the upper normal limit accord-
ing to the local laboratory range), and treatment with
DMARDs in mono- or combination therapy (methotrex-
ate, sulfasalazine, hydroxychloroquine, leflunomide) in a
stable dose during the previous 6 weeks. Exclusion criteria
are: former treatment with biologic agents, known intoler-
ance to methotrexate (patient should tolerate at least
7.5 mg/week), intramuscular, intraarticular or intravenous
glucocorticoid administration <6 weeks prior to inclusion,
oral glucocorticoid administration >5 mg/day, changes in
oral glucocorticoid dose <3 months prior to inclusion,
liver enzymes >2× the upper limit of normal range at
screening, current and/or imminent wish to become preg-
nant, contraindications for TNF-alpha-inhibiting treat-
ment, contraindications for MRI, known alcohol/drug
abuse, and a physical or mental state that impedes the
ability to give informed consent and show compliance
with the study program. Non-protocoled use of MRI or
ultrasonography to visualize joint inflammation is not
allowed during screening or study periods.Interventions
Participants are randomized into one of two groups: (A)
a treatment strategy based on DAS28 (control group) or
(B) treatment strategy based on DAS28 and MRI (inter-
vention group). Disease activity will be monitored sys-
tematically every 4 months by the CRP-based DAS28
(DAS28-CRP) [21,22] (intervention and control groups)
and by DAS28-CRP and MRI of the dominant hand
and wrist (intervention group only) (Figure 2).
Control group
If the patients at a scheduled visit shows unsatisfactory
inflammatory activity, which is defined as the presence
of at least one clinically swollen joint (assessed by the
rheumatologist) and DAS28-CRP >3.2, the treatment
will be intensified according to the predefined treatment
algorithm (Figure 3).
Intervention group
The intervention group will, in addition to treatment in-
tensification based on the DAS28-CRP, have their treat-
ment intensified in case of MRI BME. Thus, treatment is
intensified according to the predefined treatment algo-
rithm if the patient exhibits unsatisfactory inflammatory
activity, which is defined as the presence of at least one
clinically swollen joint (assessed by the rheumatologist)
and DAS28-CRP >3.2 and/or MRI-detected BME.
Figure 2 Intervention. The participants will be randomized 1:1 into either a treatment strategy based on DAS28 (control group) or a treatment
strategy based on DAS28 and MRI (intervention group). Disease activity will be monitored systematically every 4 months by the CRP-based disease
activity score (DAS28-CRP) (control and intervention groups) and presence of MRI BME (intervention group only).
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At the time of inclusion, the patient will receive DMARD
monotherapy treatment in less than the maximum or
maximum tolerated dose (step 1 or 2) or combination
treatment (2a) in the form of two- or three-drug therapy
(Figure 3). If the patient is receiving three-drug therapy, at
least one of the preparations must be administered at less
than the “maximum inclusion dose,” which is defined as
methotrexate (MTX) 25 mg/week (or the maximum toler-
ated dose if 25 mg/week is not tolerated), sulphasalazine
(SSZ) 2 g/day (or the maximum tolerated dose if 2 g/day
is not tolerated) and hydroxychloroquine (HCQ) 200 mg/
day (or the maximum tolerated dose if 200 mg/day is not
tolerated). If the patient exhibits unsatisfactory inflamma-
tory activity at step 1, the dose of the DMARD is escalated
within 4 weeks to the maximum tolerated dose (step 2). If
the patient exhibits unsatisfactory inflammatory activity at
treatment step 2, the patient moves one step up the treat-
ment ladder to DMARD combination therapy (MTX,
SSZ, HCQ) at the maximum tolerated doses (step 3). If
less than two of these are tolerated at the minimum dose,
treatment with leflunomide (LEF) monotherapy is started
before another step up the treatment ladder. From step 3
to 4 the patient switches treatment to tumor necrosis fac-
tor (TNF)-alpha inhibitor treatment, which at step 4 will
be adalimumab treatment combined with DMARD mono-
therapy in the form of MTX, LEF or SSZ (in prioritized se-
quence) at the maximum tolerated dose. From step 4 to 5,
the patients switch to a different TNF-alpha inhibitor in
accordance with the local guidelines. Supplementary treat-
ment with MTX, LEF or SSZ monotherapy (in prioritized
sequence) at the maximum tolerated dose is continued. At
treatment steps 6, 7 and 8, the patient is switched to a dif-
ferent biological treatment (preferably with another mode
of action than TNF-alpha inhibitors) combined withDMARD monotherapy as mentioned above in accordance
with the local guidelines. If the patient does not at any
time during the study period exhibit unsatisfactory inflam-
matory activity, the inclusion treatment will be maintained
throughout the study period.
In both the control and intervention group, intraarti-
cular glucocorticoid treatment must be administered at
the ordinary 4-monthly visits (maximum 4 ml) in clin-
ically swollen joints and may be administered in the
intervening 4-month period (further maximum of 4 ml
glucocorticoids per 4-month period). However, gluco-
corticoid administration should be avoided <6 weeks
before the scheduled ordinary visit. NSAID (non-steroid
anti-inflammatory drug) treatment is only permitted in
stable doses during the study period.
Stepping up the treatment ladder can only occur at
the ordinary 4-month study visit in the case of unsatis-
factory inflammatory activity as described above. An ex-
ception is if the patient exhibits “unacceptably high
disease activity,” which is defined as DAS28-CRP >5.1
and ≥1 clinically swollen joint, with the findings not pos-
sibly being explained by a different disease. Then, if the
patient has not changed treatment at the recent study
visit, and the patient already has received the permitted
dose of intraarticular glucocorticoids according to the
protocol, the patient is allowed to move one step up the
treatment ladder, and the following visit will be 4 months
after the treatment changes.
Procedures
During the 2-year study period, the patients will have seven
visits in the outpatient clinic with 4-month intervals (see
Figure 2). The time from the screening visit to inclusion
should not exceed 4 weeks. An overview of visits and corre-
sponding assessments is shown in Table 1. If the patient is
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Figure 3 Treatment algorithm. Step 1: DMARD monotherapy at less than the maximum tolerated dose (maximum dose: up to MTX 25 mg/week,
SSZ 3 g/day, HCQ 400 mg/day or LEF 20 mg/day). Step 2: DMARD monotherapy at the maximum tolerated dose (maximum dose: up to MTX
25 mg/week, SSZ 3 g/day, HCQ 400 mg/day or LEF 20 mg/day. Minimum dose: min. MTX 7.5 mg/week, SSZ 1 g/day, HCQ 200 mg/day, LEF
10 mg/day). Step 2a: DMARD combination therapy at less that the maximum tolerated doses (maximum dose up to MTX 25 mg/week, SSZ 2 g/
day and HCQ 200 mg/day). Step 3: DMARD combination therapy at the maximum tolerated doses (maximum dose up to MTX 25 mg/week, SSZ
3 g/day and HCQ 400 mg/day). Step 3a: LEF (in case of adverse reactions or intolerance to two of the following: MTX, SSZ, HCQ in three-drug
therapy, change to monotherapy LEF 20 mg/day without prior loading dose). Step 4: MTX or LEF or SSZ (prioritized sequence) at the maximum
tolerated dose + adalimumab* Step 5: MTX or LEF or SSZ (prioritized sequence) at the maximum tolerated dose + other TNF-alpha inhibitor*
(selected by the attending rheumatologist). Steps 6, 7 and 8: MTX or LEF or SSZ (prioritized sequence) at the maximum tolerated dose + biological
treatment* (preferably non-TNF-alpha inhibitor). *Biological treatment is administered in combination with DMARD monotherapy treatment in
the following prioritized order: MTX, LEF, SSZ. If the patient develops adverse reactions to the supplemented DMARD monotherapy treatment
and is unable to tolerate the minimum dose, a switch must be made to another DMARD in the mentioned prioritized order.
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attend follow-up visits at the time points for visits 4 and 7
(years 1 and 2) having the related procedures performed.
Medical history and demographic data
At the screening visit, information on socio-demographic
data (gender, marital status, smoking history, employment
and educational status), year of onset of RA symptoms,
year of diagnosis, current and past medical history, comor-
bidity, current and past treatment with DMARDs and/or
steroids and/or NSAIDS (start date, dose, frequency, end
date) will be obtained, and a physical examination including
height, weight, blood pressure (BP) and an electrocardio-
gram (ECG) will be carried out.
Clinical and laboratory assessments
At the screening visit and at all following visits, a 40
swollen and tender joint count (right and left shoulderjoints, elbow joints, wrists, MCP joints, PIP joints, 1st IP
joint, knee joints, ankle joints and MTP joints) is carried
out, and DAS28-CRP is calculated based on 28 joints
(right and left shoulder, elbow, wrist, MCP, PIP, 1st IP
and knee joints). As per standard of care, routine blood
tests (hemoglobin, leucocyte and differential count, CRP,
thrombocytes, albumin, creatinine, electrolytes, alkaline
phosphatases and ALAT) are carried out. To ensure kid-
ney function ahead of contrast injection in relation to
MRI, a blood sample is collected for creatinine, and the
glomerular filtration rate (GFR) is calculated. Blood and
urine samples for biobank storage are collected at each
study visit from baseline and in case the patient changes
treatment between the scheduled 4-month visits.
Patient-reported outcomes
The physical function is assessed at every visit using the
Health Assessment Questionnaire (HAQ) [23]. To assess
Table 1 Summary of measures to be collected
Variable
Visit number 0/Screening 1/baseline 2 3 4 5 6 7
Week −4-0 0 16 32 48 64 80 96
Demographic data
Age – years A - - - - - - -
Female sex – no. (%) A - - - - - - -
Disease duration A - - - - - - -
Duration of RA symptoms A - - - - - - -
Smoking status A - - - - - - -
Marital status A - - - - - - -
Educational and employment status A - - - - - - -
Medical history
Former and current arthritis treatment A - - - - - - -
Concomitant medication A A - - A - - A
Physical examination
40 joint assessment* (TJC/SJC) A A A A A A A A
General physical examination** A A - - A - - A
Height – cm A A - - A - - A
Weight – kg A A - - A - - A
Blood pressure and pulse A A A A A A A A
Electrocardiogram A - - - - - - -
Laboratory assessment
Routine blood tests*** A A A A A A A A
Anti-CCP and IgM-RF A - - - A - - A
Biomarker collection (blood and urine) for bio-bank - A A A A A A A
Patient reported outcomes
Patient: VAS pain, VAS global, VAS fatigue – range 0-100 A A A A A A A A
Morning stiffness - min A A A A A A A A
HAQ A A A A A A A A
SF-36 - A - - A - - A
EQ-5D - A - - A - - A
Physician’s global assessment of disease activity (VAS) 0-100 A A A A A A A A
DAS28 (CRP) score**** A A A A A A A A
Imaging
X-ray hands and feet - A - - A - - A
Controls MRI 2nd to 5th MCP and wrist - A - - A - - A
Dynamic MRI***** - A - - A - - A
Intervention MRI2nd to 5th MCP and wrist - A A A A A A A
Dynamic MRI***** - A A A A A A A
A = Assessed; − = not assessed; TJC = tender joint count; SJC = swollen joint count; anti-CCP = anti-citrullinated peptide; IgM-RF = IgM-rheumatoid factor;
VAS = visual analog scale; HAQ = health assessment questionnaire; SF-36 = short form (36) health survey; EQ-5D = EuroQol; DAS28 = disease activity score based
on assessment of 28 joints; MRI = magnetic resonance imaging; MCP = metacarpophalangeal joints.
*Right and left shoulder joints, elbow joints, wrists, MCP joints, PIP joints, 1st IP joint, knee joints, ankle joints and MTP joints.
**Inspection of the cavum oris, skin, assessment of lymph node status, heart and lung stethoscopy, examination of the abdomen, neurological examination and
additional focused examinations if the patient’s medical history suggests presence of other disease.
***Hemoglobin, leucocytes and differential count, CRP, thrombocytes, albumin, creatinine, electrolytes, alkaline phosphatases, alanine amino transaminase.
Furthermore, anti-CCP and IgM-RF are also analyzed at baseline and subsequently repeated at months 12 and 24.
****DAS28-4(crp) = 0.56*sqrt (tender joint count 28) + 0.28*sqrt (swollen joint count 28) + 0.36*ln (CRP + 1) + 0.014*GH + 0.96.
*****If technically possible.
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Form 36 questionnaire (SF-36) [24,25] and EuroQol 5
dimension 5 level (EQ-5D-L5) [26] are completed at
baseline and years 1 and 2.
At each visit, patient assessments of arthritis pain and
fatigue and physician global assessment of disease activity
on visual analog scales (0–100) and the duration of joint
morning stiffness (min) will be registered.
Imaging
MRI of unilateral 2nd to 5th MCP joints and wrist of
the dominant hand will be conducted. A coronal T1-
weighted 3D gradient echo sequence before and after
gadolinium contrast [0.1 mmol Dotarem (gadoteric acid)
per kg body weight] injection and a coronal STIR sequence
before contrast injection are performed. When possible, a
2D dynamic contrast-enhanced (DCE)-MRI sequence will
be performed during the first 5 min following the intraven-
ous gadolinium contrast injection. An additional PDF file
shows the acquired MRI sequences (see Additional file 1).
In the intervention group, MRI is performed at base-
line and every 4 months ahead of the clinical visit. An
evaluator (BE), who will be blinded to the chronology,
clinical, laboratory and other imaging data, will evaluate
the MR images for BME within 1 week after acquisition,
and the result “BME present” or “BME absent” will be
made available for the rheumatologist at the study visit.
In the control group, MRI will be conducted at baseline
and at years 1 and 2, but the investigator remains
blinded to the results of the MRI during the study
period.
Radiographs of the hands (posteroanterior view) and
feet (anteroposterior view) will be conducted at baseline
and yearly in both groups and will be kept blinded to
the investigator.
Quality assessment of all the MRIs and radiographs
will be carried out centrally by an experienced research
radiographer (JM). If the MRIs or radiographs do not
satisfy the quality requirements, a re-scan and/or repeat
radiographs will be performed.
After study termination, separate evaluations of radio-
graphs and MRIs will be carried out centrally. Both radio-
graphs and MRIs will be scored with known chronology,
but the readers will be blinded to clinical, laboratory and
other image data. There will be two experienced readers
evaluating the MRIs and x-rays, respectively.
Electronic case report form (e-CRF)
All data registration will be recorded electronically in an
e-CRF. The e-CRF has been developed to function
within the nationwide DANBIO registry [27], where
most Danish RA patients are already registered and
followed in daily practice, making it easy to handle for
the rheumatologist. The e-CRF is built of three separatecommunicating modules: one for the investigators, an-
other for the radiographers and a third for the MRI
evaluator. All are entering data into their module using
individual usernames, passwords and user rights, i.e., the
radiographers and MRI evaluators have no access to
clinical data, and the MRI evaluator is blinded to patient
data and only has access to anonymized imaging data.
When the MRI has been evaluated, “bone marrow edema
present” or “bone marrow edema absent” is entered into
the CRF, and the result will then become visible to the
investigator.
The e-CRF is “interactive,” i.e., only shows variables
that are relevant for the visit assessed and with respect
to the allocated intervention. It also specifies for the
clinician when treatment should be adjusted according
to the protocol. The randomization is done in the e-CRF
at the baseline visit. Depending on the allocated inter-
vention, an adjusted “order page” with a list of proce-
dures, which have to be ordered in relation to the
following visit, is available. Variables for all outcome
measures assessed will be entered into the e-CRF
(Table 1).
Randomization and allocation concealment
The study utilizes a computer-generated allocation con-
cealment process, which ensures that the group to which
the patients is allocated is not known before the patient
is entered into the study. Randomization and allocation
are done electronically in the e-CRF at the inclusion
visit. The randomization sequence is created by an inde-
pendent statistician (RC) using a “random number” gen-
erator, SAS statistical software (version 9.2). The
randomization sequence is entered into the e-CRF by an
independent data manager (NSK). The participants will
be given their study number and randomization group
when the physician “clicks” on a “randomization button,”
which will appear at the baseline visit. The randomization
number and assigned intervention will then be visible on
the screen. Thus, the patients are given consecutive
screening and randomization numbers, independent of
the study site.
Blinding: outcome assessor
The IMAGINE-RA study is a randomized strategy trial.
Neither patients nor the investigators are blinded to the
randomization group. The evaluator evaluating the MRIs
for presence/absence of BME will be blinded to the
chronology, clinical, laboratory and other image data, and
the investigators will be blinded to the MRIs conducted in
the control group during the study period. After all visits
have been completed, independent evaluators blinded to
the treatment arm, clinical, laboratory and other imaging
data, but not to chronology, will assess radiographs and
perform full analysis of the MR images.
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In Table 1 are listed the outcome measures assessed and
the time points at which they are collected over the 2-
year period.
Primary outcomes
The primary radiographic outcome measure is presence
vs. absence of radiographic progression after 2 years. An-
ticipating that fewer patients in the intervention group will
progress on radiographs, the primary radiographic out-
come measure is absence of radiographic progression
from baseline to week 96, which will be assessed according
to the modified Sharp/Van der Heijde score (SHS) (range
0–448) [28] separately assessing erosions and joint space
narrowing in the hand, wrist and foot joints. Progression
is defined as change in total SHS >0.
The primary clinical outcome measure is DAS28-CRP
remission (DAS28-CRP <2.6) at week 96. The DAS28-
CRP score, which is a composite score, will be calculated
based on a joint count of 28 tender (TJC) and swollen
joints (SJC) of the 40 assessed, the C-reactive protein
(CRP) value and the patient’s global assessment of the
disease on a visual analog scale (0–100).
Secondary outcomes
The secondary clinical outcome measures include the
presence of and changes in the following clinical findings:
DAS28-CRP remission (DAS28-CRP <2.6) at week 48,
ACR/EULAR remission (The 2011 ACR/EULAR Defini-
tions of Remission in Rheumatoid Arthritis Clinical Trials)
at week 48 and 96 and DAS28-CRP week 48 and 96.
The secondary imaging outcome measures include the
following radiographic and MRI findings: absence of
radiographic progression (Sharp/vdHeijde score) from
week 0–48 and 48–96 as well as change in the Sharp/
vdHeijde score from week 0–48, 0–96 and 48–96. MRI
inflammatory and destructive findings are assessed using
the semiquantitative OMERACT (Outcome Measures in
Rheumatology) scoring system, RAMRIS (RA MRI scoring
system) [29]. The following MRI secondary outcomes are
assessed: absence of progression in the MRI erosion
(RAMRIS) score from week 0–48 and 48–96, change in
the MRI erosion (RAMRIS) score from week 0–48, 0–96
and 48–96, MRI synovitis and MRI bone marrow edema
(RAMRIS) score at week 48 and 96, and change in DCE-
MRI variables [including initial rate of enhancement (IRE)
and maximum enhancement (ME)], if available, week 0–
48 and 0–96.
Several secondary patient-reported outcomes are
assessed. To assess the patients’ physical function, the
Health Assessment Questionnaire Disability Index
(HAQ-DI) [30] is calculated from the Health Assessment
Questionnaire (HAQ). Change in HAQ-DI is calculated
from week 0–48 and 0–96. To assess health-related qualityof life, the questionnaires Short-Form 36 questionnaire
(SF-36) [24,25] and the EuroQol 5 dimension 5 level
(EQ-5D-L5) [26] are assessed at baseline and yearly.
Changes in the scores are calculated from week 0–48
and 0–96.
For assessment of further secondary outcomes, blood
and urine samples will be stored in a biobank for later
analysis of various biomarkers.
Statistics
Sample size and power considerations
Primary clinical endpoint: Assuming 60% of patients in
the control group and 80% of patients in the intervention
group reach the primary clinical endpoint (DAS < 2.6) at
month 24, a group size of 64 in each group is needed to
give a statistical power of 80% (beta = 0.20) for the detec-
tion of statistically one-sided significant (p = 0.05) treat-
ment efficacy, assessed on the basis of two independent
binomially distributed proportions using Pearson’s chi-
square statistics with a chi-square approximation with a
one-sided significance level of 0.05. Based on a specified
group size of 100 patients in each group (200 in total), the
project is assessed as having a 93% chance of success with
regard to the clinical efficacy goal (statistical power 0.93).
Primary radiographic endpoint (assessed using the
Sharp/vdHeijde score):
Assuming that 75% of patients in the control groupa
and 90% of patients in the intervention group reach the
primary radiographic performance goal (no radiographic
progression) at month 24, a group size of 79 in each
group is required to give a power of 80% (beta = 0.20) for
detection of a statistically one-sided significant (p = 0.05)
treatment efficacy, assessed on the basis of two independ-
ent binomially distributed proportions using Pearson’s chi-
square statistics with a chi-square approximation with a
one-sided significance level of 0.05. Based on the specified
group size of 100 patients in each group (200 in total), the
project is assessed as having an 88% chance of success
with regard to the radiographic efficacy goal (statistical
power 0.879).
Based on “sample size” calculations of the two above-
mentioned endpoints, a total sample size of 200 has
been selected.
Statistical analysis plan
The proportion of patients in the two treatment groups
who fulfill the primary endpoints will be compared using
the chi-square test. This primary analysis will be based
on the total intention-to-treat (ITT) population, all ran-
domized patients independent of the adherence to the
study protocol. The primary statistical analysis will be
based on all usable data, irrespective of protocol devia-
tions, and missing data will primarily be replaced using
“multiple imputation” (MI), which assumes that data are
Møller-Bisgaard et al. Trials  (2015) 16:178 Page 9 of 11‘missing at random’ [31]. The MI analyses will be based
on a “Markov chain Monte Carlo” (MCMC) simulation
statement designed to fit Bayesian models to impute
values for a data set with an arbitrary missing pattern,
assuming a multivariate normal distribution for the data
(modeled in SAS). These analyses will secondarily be
supplemented by “worst-case” and “best-case” imput-
ation in the event that data are “not missing at random”
[32]. With regard to the further hypothesis-generating
component of the project, a separate analysis of the pa-
tients who adhered to the study protocol (per-protocol
analysis) will be carried out.
Data registration and monitoring
The IMAGINE-RA study is carried out in accordance
with the approved protocol and the applicable regulatory
requirements and legislation in this field. A good clinical
practice (GCP) monitoring plan has been developed in
cooperation with the GCP unit in Copenhagen to ensure
that the trial is carried out, registered and reported in
accordance with the protocol, with specified procedures
and with Danish law. Two internal monitors who will
ensure that all data have been entered correctly and in
accordance with the protocol will carry out monitoring.
If data are missing, queries will be sent electronically to
the sites. All study information will be recorded in the e-
CRF, which is developed to function within the Danish
DANBIO registry. The e-CRFs will be completed by the
investigator, project nurse and patient. To get access to
the e-CRF, a username and password are required.
Ethics approval
The regional Scientific Ethical Committee of Southern
Denmark has approved the study (project ID: S-
20110109). The study is carried out according to the
Declaration of Helsinki 2008 (Declaration of Helsinki
World Medical Association 2008) fulfilling all general
ethical considerations. All participants will receive oral
and written information about the study, and oral and
written informed consent is obtained, with the possibility
to drop out at any time.
Storage of personal information/Danish data protection
agency
To give the health authorities the option of further
evaluation, the investigator registers, inter alia, the iden-
tities of all participating patients (enough information to
link the registrations, e.g., CRFs and hospital journals)
and stores all original signed informed consent forms
and electronic CRFs. In accordance with international
regulations, the investigator stores these registrations for
a minimum of 10 years. Patient data are protected in ac-
cordance with the Danish Act on the Processing ofPersonal Data and the Danish Health Act. The Danish
Data Protection Agency has approved the project.
Adverse events
It is the investigator’s responsibility to ensure that all
serious adverse reactions/adverse events are immediately
reported to the sponsor and project leader, who are re-
sponsible for notifying the regional Biomedical Research
Ethics Committee. Reports to the regional Biomedical
Research Ethics Committee must be accompanied by
comments on the possible consequences for the trial.
The project leader is also responsible for informing the
participating departments of what a serious adverse re-
action/adverse event entails. It is also the responsibility
of the project leader to submit on an annual basis, starting
1 year after approval of the study, a list of all serious unex-
pected adverse reactions and serious adverse events that
have occurred in the period to the regional Biomedical Re-
search Ethics Committee. Reports must be accompanied
by an assessment of the safety of trial subjects.
The study was designed by the authors. Input from
AbbVie was received only at the onset of the protocol
writing. Data will be collected by the monitoring company
(ZiteLab) and will be assessed jointly by the senior biostat-
istician (RC) and the group authors, without interference
from the sponsor. The data will be interpreted and the
report written by the authors without writing support
from the sponsor. The corresponding author will have full
access to all the data in the study and have the final re-
sponsibility for the decision to submit for publication.
Discussion
This study is expected to contribute significant new
knowledge about the options for improved outcome for
RA patients by better and more sensitive disease moni-
toring using MRI and thereby ensuring optimal clinical
and radiographic disease control. The use of MRI as a
treatment guide may be valuable in individualizing the
treatment, so patients assessed as being at high risk of
erosive progression can receive appropriately intensive
treatment so disease progression can be avoided. If an
MRI-guided treatment strategy is shown to be beneficial,
implementation in daily clinical practice will also be
feasible. The availability of MRI can vary, but the exam-
ination time doing a scan for BME is short (less than
30 min), and no contrast agent has to be administered.
Thus, the procedure will be noninvasive and safe for the
patient. In addition, the MRIs only need to be evaluated
for the presence or absence of BME, meaning that the
evaluator will not need to be trained in a specific scoring
system.
The design of this study is unique and methodologically
very strict and systematic, which is essential to achieve
scientifically valid data. A weakness is however the
Møller-Bisgaard et al. Trials  (2015) 16:178 Page 10 of 11non-blinded design. The rheumatologist and patient are
not blinded to the allocated intervention, which potentially
could lead to bias. However, full blinding would require
that all seven MRIs also were done in the control group,
but not used, which was not considered feasible and ethic-
ally justified. A major strength is that all the MRI scans
will be evaluated for BME within 7 working days after ac-
quisition at a central reading center by one evaluator (BE),
who has extensive experience from previous MRI studies
[10,19,33,34]. The evaluator will be blinded to chronology,
clinical, laboratory and other image data. Consequently,
the evaluations will be consistent, which will improve
study quality and the subsequent results.
The IMAGINE-RA trial is, as far as we are aware, the
first study using MRI to guide RA treatment. The results
of the study will be of great importance for all rheuma-
tologists that treat RA patients and can potentially
change our way of monitoring RA patients and individu-
alizing the treatment so a better disease outcome can be
achieved.
Trial status
The trial is recruiting.
Endnotes
aThe AMBRA study at King Christian 10th Hospital
for Rheumatic Diseases, Graasten and Vejle Hospital, in-
volved 300 patients with RA in accordance with the
ACR 1987 classification criteria, DAS28 < 3.2, ≥1½ year’s
disease duration, unchanged anti-rheumatic treatment ≥
3 months and no biological treatment. The patients were
monitored in different outpatient courses, treated with
DMARDs and where necessary given biological treat-
ment to maintain low disease activity based on clinical
evaluation. Radiographic progression in the wrists, hands
and feet 0–24 months was seen in 25% of patients who
were anti-CCP positive and had erosive disease at the
time of inclusion. The proportion of patients with
DAS28 > 2.6 was 38% [23].
Additional file
Additional file 1: Acquired MRI-sequences in the IMAGINE-RA
study. Description of acquired MRI sequences of the wrist and MCP
joints in the IMAGINE-RA study.
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